{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T01:46:27Z","timestamp":1795225587393,"version":"4.10.3"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000875","name":"PEW Charitable Trusts","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000875","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K99DA057372"],"award-info":[{"award-number":["K99DA057372"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA057568"],"award-info":[{"award-number":["R01DA057568"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K01DA049950"],"award-info":[{"award-number":["K01DA049950"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA047347"],"award-info":[{"award-number":["R01DA047347"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajpm-online.net","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.amepre.2025.108055","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T23:24:03Z","timestamp":1755041043000},"page":"108055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Buprenorphine Dispensation After X-Waiver Elimination by Clinician Specialty"],"prefix":"10.1016","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5676-1499","authenticated-orcid":false,"given":"Elizabeth M.","family":"Stone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7702-093X","authenticated-orcid":false,"given":"Fangzhou","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Miles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5773-3705","authenticated-orcid":false,"given":"Hillary","family":"Samples","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3958-5662","authenticated-orcid":false,"given":"Mark","family":"Olfson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Crystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amepre.2025.108055_bib0001","doi-asserted-by":"crossref","unstructured":"Mackey K, Veazie S, Anderson J, Bourne D, Peterson K. Barriers and facilitators to the use of medications for opioid use disorder: a rapid review. J Gen Intern Med. 2020;35(3)(suppl 3):954\u2013963. https:\/\/doi.org\/10.1007\/s11606-020-06257-4.","DOI":"10.1007\/s11606-020-06257-4"},{"issue":"3","key":"10.1016\/j.amepre.2025.108055_bib0002","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.3821","article-title":"Use of medication for opioid use disorder among US adolescents and adults with need for opioid treatment, 2019","volume":"5","author":"Mauro","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.amepre.2025.108055_bib0003","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.27488","article-title":"Use of medication for opioid use disorder among adults with past-year opioid use disorder in the U.S., 2021","volume":"6","author":"Jones","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.amepre.2025.108055_bib0004","series-title":"To help providers fight the opioid epidemic, \u201cX The X Waiver\u201d","author":"Berk","year":"2019"},{"issue":"3","key":"10.1016\/j.amepre.2025.108055_bib0005","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamapsychiatry.2018.3685","article-title":"Buprenorphine deregulation and mainstreaming treatment for opioid use disorder: X the X waiver","volume":"76","author":"Fiscella","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.amepre.2025.108055_bib0006","unstructured":"Consolidated Appropriations Act, 2023, Pub. L. No. 117-328 (2022).https:\/\/www.congress.gov\/bill\/117th-congress\/house-bill\/2617\/text. Accessed October 22, 2024."},{"key":"10.1016\/j.amepre.2025.108055_bib0007","unstructured":"Substance Abuse and Mental Health Services Administration. Waiver elimination (MAT act); 2024. https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/waiver-elimination-mat-act. Accessed May 29, 2025."},{"issue":"16","key":"10.1016\/j.amepre.2025.108055_bib0008","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1056\/NEJMc2312906","article-title":"Buprenorphine dispensing after elimination of the waiver requirement","volume":"390","author":"Chua","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amepre.2025.108055_bib0009","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.amepre.2024.09.013","article-title":"Utilization of buprenorphine for opioid use disorder after the practitioner waiver removal","volume":"68","author":"Ali","year":"2025","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.amepre.2025.108055_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.109933","article-title":"Change in opioid and buprenorphine prescribers and prescriptions by specialty, 2016\u20132021","volume":"248","author":"Larochelle","year":"2023","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.amepre.2025.108055_bib0011","unstructured":"Practice guidelines for the administration of buprenorphine for treating opioid use disorder. In: FR 22439, 86; 2021. https:\/\/www.federalregister.gov\/documents\/2021\/04\/28\/2021-08961\/practice-guidelines-for-the-administration-of-buprenorphine-for-treating-opioid-use-disorder. Accessed August 26, 2025."},{"key":"10.1016\/j.amepre.2025.108055_bib0012","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/SAR.S150253","article-title":"Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder","volume":"9","author":"Ronquest","year":"2018","journal-title":"Subst Abuse Rehabil"},{"issue":"12","key":"10.1016\/j.amepre.2025.108055_bib0013","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/s41380-018-0094-5","article-title":"Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis","volume":"24","author":"Ma","year":"2019","journal-title":"Mol Psychiatry"},{"issue":"3","key":"10.1016\/j.amepre.2025.108055_bib0014","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2307\/1913610","article-title":"A simple, positive semi-definite, heteroskedasticity and autocorrelation consistent covariance matrix","volume":"55","author":"Newey","year":"1987","journal-title":"Econometrica"},{"issue":"4","key":"10.1016\/j.amepre.2025.108055_bib0015","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"10.1016\/j.amepre.2025.108055_bib0016","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.8469","article-title":"Medicaid unwinding and changes in buprenorphine dispensing","volume":"8","author":"Constantin","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.amepre.2025.108055_bib0017","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2025.0393","article-title":"Trends in access to medications for opioid use disorder","volume":"6","author":"Gupta","year":"2025","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.amepre.2025.108055_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108784","article-title":"Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder?","volume":"225","author":"Dunphy","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.amepre.2025.108055_bib0019","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/add.14436","article-title":"Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder","volume":"114","author":"Jones","year":"2019","journal-title":"Addiction"},{"key":"10.1016\/j.amepre.2025.108055_bib0020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.addbeh.2018.09.027","article-title":"Implementing peer recovery services for overdose prevention in Rhode Island: an examination of two outreach-based approaches","volume":"89","author":"Waye","year":"2019","journal-title":"Addict Behav"},{"issue":"10","key":"10.1016\/j.amepre.2025.108055_bib0021","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1176\/appi.ajp.21111141","article-title":"Impact of COVID-19 telehealth policy changes on buprenorphine treatment for opioid use disorder","volume":"179","author":"Lin","year":"2022","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.amepre.2025.108055_bib0022","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1001\/jamainternmed.2020.7497","article-title":"Assessment of filled buprenorphine prescriptions for opioid use disorder during the coronavirus disease 2019 pandemic","volume":"181","author":"Nguyen","year":"2021","journal-title":"JAMA Intern Med"}],"container-title":["American Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379725005239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379725005239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:50:37Z","timestamp":1779771037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749379725005239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0749379725005239"],"URL":"https:\/\/doi.org\/10.1016\/j.amepre.2025.108055","relation":{},"ISSN":["0749-3797"],"issn-type":[{"value":"0749-3797","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Buprenorphine Dispensation After X-Waiver Elimination by Clinician Specialty","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amepre.2025.108055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108055"}}